Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment?
Authors:
- 23 October 2007
- journal article
- editorial
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 5 (1) , 10-11
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene and codons 12 and 13 of the KRAS gene in non-small cell lung cancer (NSCLC) patients treated with erlotinib in National Cancer Institute of CancerJournal of Clinical Oncology, 2007
- Update onEpidermal Growth Factor ReceptorMutations in Non–Small Cell Lung CancerClinical Cancer Research, 2006
- Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor TherapyClinical Cancer Research, 2006
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLOS Medicine, 2005